Human Immunodeficiency Virus–Associated Myocarditis
F Aziz, S Doddi, S Penupolu

Citation

Abstract
Alterations in the immune system likely play an important role in the pathogenesis of heart muscle disease in HIV-infected patients. Immune Reconstitution Inflammatory Syndrome is a well-known entity causing myocarditis in HIV-infected patients. To our knowledge, a correlation of direct HIV-associated myocarditis has not been described previously. We report a case of acute myocarditis presenting with complete heart block in a patient with AIDS. The case underscores the importance of recognizing this potential complication of AIDS and calls for renewed vigilance concerning cardiac manifestations of HIV.

INTRODUCTION
Human immunodeficiency virus (HIV) infection and AIDS have a well-recognized association with myocarditis and dilated cardiomyopathy. This increased predisposition is multifactorial and may include the direct effects of HIV itself, co-infection by opportunistic organisms, toxic effects of commonly used medications or illicit drugs, and nutritional deficiencies. Further, autoimmunity can be an important contributor to the pathogenesis of cardiomyopathy in these patients as many studies demonstrated the presence of cardiac-specific antibodies in HIV patients when compared with HIV negative controls. Thus, although the precise mechanisms are poorly understood, alterations in the immune system likely play an important role in the pathogenesis of heart muscle disease in HIV-infected patients.

Immune reconstitution inflammatory syndrome (IRIS) is one such example of an alteration in the immune system that is exclusively recognized in the HIV/AIDS population. IRIS is a collection of inflammatory disorders in which clinical deterioration occurs despite recovery of the immune system after highly active antiretroviral therapy (HAART). Numerous manifestations of disease that involve several different organ systems have been described. Despite the growing incidence of IRIS and the increased prevalence of myocarditis and cardiomyopathy in HIV-infected patients, involvement of the cardiovascular system is not recognized as a manifestation of IRIS. There are a few case reports, which describe the myocarditis in AIDS patients immediately after the start of HAART, but here we describe a patient with AIDS in whom myocarditis developed even before the start of HAART. He presented with myocarditis and later he was found to be HIV positive. To our knowledge an association between purely HIV–associated myocarditis has not been described previously.

REPORT OF CASE
A 31-year-old man with no past medical presented to the emergency department with a 2-day history of light-headedness and palpitations. Associated symptoms included mild dyspnea on exertion, vague abdominal discomfort, nausea, vomiting, diarrhea, and generalized fatigue. He denied fever, chest pain, orthopnea, paroxysmal nocturnal dyspnea, history of syncope, or known previous cardiac disease.

Vital signs recorded at triage were a temperature of 35.2°C, blood pressure of 79/43 mm Hg, and pulse rate of 45 beats/min. Physical examination revealed scleral-icterus, coarse breath sounds bilaterally, mild abdominal distention, and minimal leg edema. Cardiac examination demonstrated a non-displaced point of maximal impulse; a regular rhythm without murmurs, rubs, or gallops; and no jugular venous distention. Laboratory data were obtained (Table 1).
Figure 1

Table 1:

<table>
<thead>
<tr>
<th>Test</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na</td>
<td>135 mEq/L</td>
</tr>
<tr>
<td>X</td>
<td>4.0 mEq/L</td>
</tr>
<tr>
<td>BUN</td>
<td>8 mg/dl</td>
</tr>
<tr>
<td>Cr</td>
<td>0.9 mg/dl</td>
</tr>
<tr>
<td>Blood Glucose</td>
<td>77 mg/dl</td>
</tr>
<tr>
<td>ESR</td>
<td>49</td>
</tr>
<tr>
<td>Lyme Titer</td>
<td>&lt;0.91</td>
</tr>
<tr>
<td>CPK</td>
<td>199 ng/ml</td>
</tr>
<tr>
<td>CPK Mil fraction</td>
<td>0.2 ng/ml</td>
</tr>
<tr>
<td>ANA</td>
<td>Negative</td>
</tr>
<tr>
<td>Troponin</td>
<td>0.23 ng/ml</td>
</tr>
</tbody>
</table>

High troponin in first set of lab was highly indicative of myocarditis. During initial evaluation, the patient suddenly developed third degree heart block on the monitor but he remained asymptomatic (Figure 1).

Figure 2

Subsequent electrocardiography (ECG) showed sinus tachycardia and complete heart block. Transthoracic echocardiography demonstrated a left ventricular ejection fraction of 40% with mild global hypokinesis, moderate mitral regurgitation, and small pericardial effusion. No prior echocardiograms were available for comparison. Chest radiography showed bilateral good air entry. The patient was admitted to the cardiac care unit, where he experienced multiple episodes of complete heart block. Transcutaneous pacemakers were placed to deal with the complete heart block. He was further managed with intravenous fluids and electrolyte replenishment. Work up for the myocarditis was sent which included ESR, Lyme Titer, ANA, serology for parvo, EBV and HIV. Empirical broad-spectrum antibiotics were administered. ESR was elevated. Later, Patient’s rapid HIV came out positive, which was confirmed by western blot test. All other test was reported negative including blood culture for staphylococcus and streptococcus. Stool examination was negative for ova and parasites. At this time, diagnosis of HIV-associated myocarditis was made after ruling out other possible causes.

Patient’s troponin started trending down in two days and patient’s EKG started showing normal sinus rhythm without any blocks. No permanent pace maker was placed and patient was referred for electrophysiological study.

DISCUSSION

The actual etio-pathogenesis of cardiac injury in HIV infection is not clear. It is however generally agreed that several factors come into play either singly or in combination to produce cardiac pathology. There is a wide range of hypotheses regarding the pathogenesis of HIV associated heart muscle disease. These include myocardial invasion with HIV itself, opportunistic infections, viral infections, and autoimmune response to viral infection, drug-related cardiac toxicity, nutritional deficiencies, endothelial dysfunction, autonomic dysfunction, and prolonged immunosuppression.

Myocarditis is defined histologically by the Dallas criteria, which require the presence of an inflammatory infiltration of the myocardium with adjacent myocytes necrosis or degeneration that is not typical of the ischemic damage associated with coronary artery disease. However, the use of this strict definition may be inappropriate in the context of an impaired immune response.

Three histological patterns of myocarditis have been described in patients with AIDS:

- Lymphocytic infiltration with myocyte necrosis 17, which meets the Dallas criteria;
- Lymphocytic infiltration without inflammation 18; and
- Myocyte damage without evidence of inflammatory infiltrate 19

The prevalence of myocarditis in HIV infected patients has been difficult to establish with estimates ranging from 6% to 52%. The virus itself may cause myocarditis in HIV infection, either directly or indirectly via autoimmune processes, or via one of many opportunistic organisms. No specific etiologic factor was found in more than 80% of cases of myocarditis in one series. Many organisms have been implicated in the development of myocarditis in HIV infected patients.

The diagnosis of myocarditis requires a high index of suspicion based upon symptoms and/or compatible physical
findings such as fever and signs of heart failure.

Non-specific ECG changes may occur such as sinus tachycardia, conduction defects and repolarization abnormalities, and there may be radiological evidence of cardiac enlargement or pulmonary edema.

Echocardiography offers a practical, non-invasive means of assessing cardiac size and function. The Echo features of myocarditis are non-specific and often identical to those associated with cardiomyopathy. Indeed, differentiation between the two conditions can only be made histologically. Some workers have demonstrated dyskinesia of the left ventricle with or without dilatation or generalized four-chamber enlargement.

Clinical presentation of HIV associated myocarditis in symptomatic patients is generally similar to myocarditis due to other causes. The absence of symptoms and signs of heart disease does not however exclude cardiac involvement, as occurrence of sub-clinical cardiac abnormalities with possible fatal consequences in this population has been described. Diagnosis requires the possibility of cardiac involvement to be borne constantly in mind and suspected if symptoms and/or compatible physical findings emerge. Electrocardiography (ECG) is a useful screening tool in patients with HIV infection, and ECG changes may precede echocardiographic abnormalities. Patients with abnormal ECG patterns should be further investigated.

Echocardiography has been shown to be extremely useful for the diagnosis and monitoring of HIV associated myocardial disease. Computed tomography or magnetic resonance imaging may help but are not widely used for diagnosis. The need for routine myocardial biopsy is controversial and associated risks are significant – sensitivity is low, especially in patchy lesions, and beyond research protocols its use is limited to patients with extensive cardiac damage with no identifiable cause.

Treatment for HIV related myocarditis is generally similar to that for non-HIV related myocarditis. Patients with myocarditis have enhanced sensitivity to digoxin and anticoagulation presents risks to patients with cerebral vasculopathy and possible aneurysm formation. The use of immunosuppressive regimens is controversial and no convincing benefits have been reported other than with intravenous immunoglobulin, whose efficacy may reflect inhibition of cardiac auto antibodies by competition with Fc receptors or dampened effects of cytokines and cellular growth factors.

The introduction of highly active antiretroviral therapy (HAART) regimens has substantially modified the course of HIV disease by lengthening survival and improving quality of life of HIV-infected patients. There is also good evidence that HAART significantly reduces the incidence of cardiovascular manifestations of HIV infection. By preventing opportunistic infections and reducing the incidence of myocarditis, HAART regimens have reduced the prevalence of HIV-associated myocarditis to about 30%.

Cardiovascular abnormalities are frequent in HIV infected patients but clinically discrete. Cardiologists and physicians all over the world are reporting more heart muscle disease. With current advances in HIV/AIDS management and increased survival, cardiac manifestations of HIV disease including HIV related myocardial disease will become more important and encountered more frequently. Since cardiac complications are often clinically in apparent, periodic screening of HIV positive patients is recommended, especially in those with low CD4 counts or receiving treatment with cardiotoxic drugs. The heart may be a marker of the HIV infected patient’s overall health, and a decline in cardiac function should trigger more comprehensive evaluation. As the role of infection and inflammation in many other cardiovascular diseases is now recognized, identification of the molecular mechanisms of HIV related myocarditis might have broader implications for a wide range of patients.

References

7. Barbarinia G, Barbaro G. Incidence of the involvement of
the cardiovascular system in HIV infection. AIDS. 2003;17(suppl 1):S46-S50.
Author Information

Fahad Aziz, MD
Jersey City Medical Center

Sujatha Doddi, MD
Jersey City Medical Center

Sudheer Penupolu, MD
Jersey City Medical Center